Cardiomyopathy is the leading cause of mortality in patients with DMD. Compared with their healthy counterparts, patients with DMD — including those with preserved left ventricular ejection fraction ...

“In support to recent literature in arrhythmogenic cardiomyopathy, our cohort data showed that the protective effect of a negative genetic testing on disease progression was a stronger predictor than ...

Monitoring for Chemotherapy-Related Cardiotoxicity in the Form of Left Ventricular Systolic Dysfunction: A Review of Current Recommendations The following represents disclosure information provided by ...

The FDA on Friday approved aficamten (Myqorzo) for symptomatic obstructive hypertrophic cardiomyopathy (HCM), drugmaker ...

Panel A shows a cross-section of a normal heart (top) and an endomyocardial biopsy sample from a normal heart (bottom; with hematoxylin and eosin staining) that shows normal histologic characteristics ...

FDA approved CYTK's Myqorzo for oHCM. It reduces heart's pumping ability, has a warning for heart failure and expected to ...

Researchers identified distinct demographic, clinical, and serologic predictors of incident LVSD and cardiac recovery among patients with SSc.

Cytokinetics has announced that the US Food and Drug Administration (FDA) has approved MYQORZO (aficamten) tablets in 5mg, ...

Medical researchers around the world continue to discover new ways Apple Watch can help save your life. A new study from researchers at the Mayo Clinic offers a deeper look at the Apple Watch’s ECG ...

Please provide your email address to receive an email when new articles are posted on . An AI model may help to detect asymptomatic heart failure using a single-lead ECG. Early diagnosis could improve ...